{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:32:08Z","timestamp":1788316328268,"version":"build-2803163510"},"reference-count":166,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>In recent years, there has been a growing trend towards the utilization of immunotherapy techniques for the treatment of cancer. Some malignancies have acquired significant progress with the use of cancer vaccines, immune checkpoint inhibitors, and adoptive cells therapy. Scholars are exploring the aforementioned methods as potential treatments for advanced prostate cancer (PCa) due to the absence of effective adjuvant therapy to improve the prognosis of metastatic castration-resistant prostate cancer (mCRPC). Immunotherapy strategies have yet to achieve significant advancements in the treatment of PCa, largely attributed to the inhibitory tumor microenvironment and low mutation load characteristic of this malignancy. Hence, researchers endeavor to address these challenges by optimizing the design and efficacy of immunotherapy approaches, as well as integrating them with other therapeutic modalities. To date, studies have also shown potential clinical benefits. This comprehensive review analyzed the utilization of immunotherapy techniques in the treatment of PCa, assessing their advantages and obstacles, with the aim of providing healthcare professionals and scholars with a comprehensive understanding of the progress in this field.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1544882","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T04:06:14Z","timestamp":1741752374000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["The application of emerging immunotherapy in the treatment of prostate cancer: progress, dilemma and promise"],"prefix":"10.3389","volume":"16","author":[{"given":"Jizhong","family":"Che","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingheng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongguo","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengchao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yankai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00249-2","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2021.03.009","article-title":"Drug and molecular radiotherapy combinations for metastatic castration resistant\u00a0prostate cancer","author":"Staniszewska","year":"2021","journal-title":"Nucl Med Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a030635","article-title":"Treatment of advanced prostate cancer-A review of current therapies and future promise","volume":"8","author":"Sumanasuriya","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ajur.2018.11.005","article-title":"Metastatic prostate cancer remains incurable, why","volume":"6","author":"Dong","year":"2019","journal-title":"Asian J Urol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Daly","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241814347","article-title":"Emerging immunotherapy approaches for treating prostate cancer","volume":"24","author":"Meng","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.840348","article-title":"Tumor microenvironment-mediated immune profiles characterized by distinct survival outcome and immunotherapeutic efficacy in breast cancer","volume":"13","author":"Xu","year":"2022","journal-title":"Front Genet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56010015","article-title":"Tumor microenvironment","volume":"56","author":"Arneth","year":"2019","journal-title":"Medicina (Kaunas)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2020.10.005","article-title":"The tumor microenvironment and immunotherapy in prostate and bladder cancer","volume":"47","author":"Nair","year":"2020","journal-title":"Urol Clin North Am"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: A therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e4","article-title":"Regulatory T cells in tumor microenvironment and approach for anticancer immunotherapy","volume":"20","author":"Kim","year":"2020","journal-title":"Immune Netw"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4103\/aja202283","article-title":"Cancer-cell-intrinsic mechanisms shaping the immunosuppressive landscape of prostate cancer","volume":"25","author":"Zhu","year":"2023","journal-title":"Asian J Androl"},{"key":"B17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-019-0787-5","article-title":"Tumor neoantigens: from basic research to clinical applications","volume":"12","author":"Jiang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Abeshouse","year":"2015","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13000-020-00971-7","article-title":"High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas","volume":"15","author":"Mei","year":"2020","journal-title":"Diagn Pathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","volume":"6","author":"Maleki Vareki","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","article-title":"Immune evasion in cancer: Mechanistic basis and therapeutic strategies","author":"Vinay","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer(\u2606)","volume":"33","author":"Niu","year":"2022","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj9779","article-title":"Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors","volume":"14","author":"Kaptein","year":"2022","journal-title":"Sci Transl Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01321","article-title":"L-selectin enhanced T cells improve the efficacy of cancer immunotherapy","volume":"10","author":"Watson","year":"2019","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80066-7","article-title":"The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes","volume":"10","author":"Vonderheide","year":"1999","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-011-8214-1","article-title":"Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas","volume":"50","author":"Finn","year":"2011","journal-title":"Immunol Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"NPJ Vaccines"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4161\/21645515.2014.973317","article-title":"Antigen-specific vaccines for cancer treatment","volume":"10","author":"Tagliamonte","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00241-8","article-title":"Cancer vaccines: platforms and current progress","volume":"6","author":"Lei","year":"2025","journal-title":"Mol BioMed"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.505","article-title":"Survival of castration-resistant prostate cancer patients treated with dendritic-tumor cell hybridomas is negatively correlated with changes in peripheral blood CD56(bright) CD16(-) natural killer cells","volume":"11","author":"Haque Chowdhury","year":"2021","journal-title":"Clin Transl Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.04.002","article-title":"Mechanisms and dynamics of T cell-mediated cytotoxicity in vivo","volume":"38","author":"Halle","year":"2017","journal-title":"Trends Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat Rev Drug Discovery"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00788-w","article-title":"Vaccine therapies for cancer: then and now","volume":"16","author":"Morse","year":"2021","journal-title":"Target Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/869718","article-title":"Targeting antigens to dendritic cell receptors for vaccine development","volume":"2013","author":"Apostolopoulos","year":"2013","journal-title":"J Drug Delivery"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-13-0108","article-title":"Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer","volume":"2","author":"Gulley","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-9960-9","article-title":"HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer","volume":"32","author":"Sonpavde","year":"2014","journal-title":"Invest New Drugs"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.12.010","article-title":"A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802","volume":"68","author":"DiPaola","year":"2015","journal-title":"Eur Urol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1062190","article-title":"Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809)","volume":"11","author":"McNeel","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"B42","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00262-015-1660-1","article-title":"Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression","volume":"64","author":"Noguchi","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000063","article-title":"A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer","volume":"38","author":"Prue","year":"2015","journal-title":"J Immunother"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b14-00518","article-title":"Survivin and PSMA loaded dendritic cell vaccine for the treatment of prostate cancer","volume":"38","author":"Xi","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10883","article-title":"Samarium-153-EDTMP (Quadramet\u00ae) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial","volume":"7","author":"Heery","year":"2016","journal-title":"Oncotarget"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-15-0189","article-title":"Tn-MUC1 DC vaccination of rhesus macaques and a phase I\/II trial in patients with nonmetastatic castrate-resistant prostate cancer","volume":"4","author":"Scheid","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.eururo.2015.12.050","article-title":"A phase 2 randomized controlled trial of personalized peptide vaccine immunotherapy with low-dose dexamethasone versus dexamethasone alone in chemotherapy-naive castration-resistant prostate cancer","volume":"70","author":"Yoshimura","year":"2016","journal-title":"Eur Urol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13397","article-title":"Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine","volume":"108","author":"Koga","year":"2017","journal-title":"Cancer Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2017.01.007","article-title":"Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study","volume":"19","author":"Kongsted","year":"2017","journal-title":"Cytotherapy"},{"key":"B50","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00262-017-1994-y","article-title":"Phase I\/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer","volume":"66","author":"Lilleby","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13278","article-title":"Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer","volume":"108","author":"Obara","year":"2017","journal-title":"Cancer Sci"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2027-6","article-title":"Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer","volume":"66","author":"Sonpavde","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B53","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40425-018-0333-y","article-title":"Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine","volume":"6","author":"Wargowski","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01701","article-title":"Phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP [MVI-816]) in patients with progressive, nonmetastatic, castration-sensitive prostate cancer","volume":"37","author":"McNeel","year":"2019","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000655","article-title":"Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer","volume":"8","author":"Abdul Sater","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-0945","article-title":"Multicenter phase I trial of a DNA vaccine encoding the androgen receptor ligand-binding domain (pTVG-AR, MVI-118) in patients with metastatic prostate cancer","volume":"26","author":"Kyriakopoulos","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02498-8","article-title":"Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial","volume":"69","author":"Noguchi","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2020-001157","article-title":"Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I\/II clinical trial","volume":"8","author":"Schuhmacher","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002374","article-title":"Phase I study of a multitargeted recombinant Ad5 PSA\/MUC-1\/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Bilusic","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002931","article-title":"Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T","volume":"9","author":"Dorff","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03024-0","article-title":"Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial","volume":"70","author":"Filaci","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3892\/or.2020.7847","article-title":"A randomized phase III trial of personalized peptide vaccination for castration\u2212resistant prostate cancer progressing after docetaxel","volume":"45","author":"Noguchi","year":"2021","journal-title":"Oncol Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002254","article-title":"Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer","volume":"9","author":"Sinha","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004198","article-title":"Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)","volume":"10","author":"McNeel","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24267","article-title":"Long-term first-in-man Phase I\/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy","volume":"82","author":"Tryggestad","year":"2022","journal-title":"Prostate"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005702","article-title":"First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)","volume":"11","author":"Autio","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34448","article-title":"Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring","volume":"152","author":"Lilleby","year":"2023","journal-title":"Int J Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/oncolo\/oyad058","article-title":"Flutamide with or without PROSTVAC in non-metastatic castration resistant (M0) prostate cancer","volume":"28","author":"Madan","year":"2023","journal-title":"Oncologist"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008067","article-title":"Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer","volume":"11","author":"McNeel","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2022.12.002","article-title":"A phase 2, double-blind, randomized controlled trial of PROSTVAC in prostate cancer patients on active surveillance","volume":"9","author":"Parsons","year":"2023","journal-title":"Eur Urol Focus"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/ebm.2024.10021","article-title":"A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms","volume":"249","author":"Zareian","year":"2024","journal-title":"Exp Biol Med (Maywood)"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.641307","article-title":"Moving on from sipuleucel-T: new dendritic cell vaccine strategies for prostate cancer","volume":"12","author":"Sutherland","year":"2021","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1009982","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Tanimoto","year":"2010","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.2c12843","article-title":"MUC1 glycopeptide vaccine modified with a galNAc glycocluster targets the macrophage galactose C-type lectin on dendritic cells to elicit an improved humoral response","volume":"145","author":"Gabba","year":"2023","journal-title":"J Am Chem Soc"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2011.1292","article-title":"Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor immune response in an immunocompetent murine model of human prostate cancer","volume":"40","author":"Wenner","year":"2012","journal-title":"Int J Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3892\/ijo.18.3.599","article-title":"Enhancement of tumor radioresponse by docetaxel: Involvement of immune system","volume":"18","author":"Mason","year":"2001","journal-title":"Int J Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2022.03.004","article-title":"Methodological advances in the design of peptide-based vaccines","volume":"27","author":"Kalita","year":"2022","journal-title":"Drug Discovery Today"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10010070","article-title":"Antitumor peptide-based vaccine in the limelight","volume":"10","author":"Kumai","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1210044","article-title":"Peptide-based vaccine for cancer therapies","volume":"14","author":"Buonaguro","year":"2023","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1133324100","article-title":"Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses","volume":"100","author":"Gnjatic","year":"2003","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2014.1002723","article-title":"Feuchtinger: Rapid generation of NY-ESO-1-specific CD4(+) T(HELPER)1 cells for adoptive T-cell therapy","volume":"4","author":"Kayser","year":"2015","journal-title":"Oncoimmunology"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.682492","article-title":"Telomerase as a target for therapeutic cancer vaccines and considerations for optimizing their clinical potential","volume":"12","author":"Ellingsen","year":"2021","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663865","article-title":"Combining a universal telomerase based cancer vaccine with ipilimumab in patients with metastatic melanoma - five-year follow up of a phase I\/IIa trial","volume":"12","author":"Aamdal","year":"2021","journal-title":"Front Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12470","article-title":"The immune system and cancer evasion strategies: therapeutic concepts","volume":"279","author":"Muenst","year":"2016","journal-title":"J Intern Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11912-018-0712-z","article-title":"Immunotherapy in prostate cancer: teaching an old dog new tricks","volume":"20","author":"Comiskey","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2015.1118348","article-title":"Prospects for the future of prostate cancer vaccines","volume":"15","author":"Madan","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"B90","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11934-019-0931-3","article-title":"Immunotherapy in metastatic castration-resistant prostate cancer: past and future strategies for optimization","volume":"20","author":"Reimers","year":"2019","journal-title":"Curr Urol Rep"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100164","article-title":"Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches","volume":"23","author":"Marshall","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-32656-2_7","article-title":"Immunological complexity of the prostate cancer microenvironment influences the response to immunotherapy","volume":"1210","author":"Prokhnevska","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1097\/mou.0000000000000433","article-title":"Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg","volume":"27","author":"Laccetti","year":"2017","journal-title":"Curr Opin Urol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/nature09744","article-title":"The genomic complexity of primary human prostate cancer","volume":"470","author":"Berger","year":"2011","journal-title":"Nature"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.225","article-title":"Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer","volume":"36","author":"Chouaib","year":"2017","journal-title":"Oncogene"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1172\/jci96268","article-title":"Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy","volume":"128","author":"Jayaprakash","year":"2018","journal-title":"J Clin Invest"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15817","article-title":"The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort","volume":"8","author":"Ness","year":"2017","journal-title":"Oncotarget"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-15-2042","article-title":"The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer","volume":"22","author":"Gevensleben","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1524-0","article-title":"A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates","volume":"63","author":"Jochems","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.69.1584","article-title":"Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J Clin Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.07.032","article-title":"Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors","volume":"78","author":"Fizazi","year":"2020","journal-title":"Eur Urol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the checkMate 650 trial","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24110","article-title":"Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial","volume":"81","author":"Shenderov","year":"2021","journal-title":"Prostate"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01991-4","article-title":"Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study","volume":"128","author":"Rodriguez-Vida","year":"2023","journal-title":"Br J Cancer"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10547","article-title":"Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer","volume":"7","author":"Graff","year":"2016","journal-title":"Oncotarget"},{"key":"B107","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/jco.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"52810","DOI":"10.1136\/jitc-2020-000642","article-title":"A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone","volume":"8","author":"Graff","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-019-0176-8","article-title":"A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer","volume":"23","author":"Ross","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B110","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.eururo.2022.02.023","article-title":"Pembrolizumab plus docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 cohort B study","volume":"82","author":"Yu","year":"2022","journal-title":"Eur Urol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00451-5","article-title":"Single-dose (177)Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Lancet Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00233","article-title":"Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J Clin Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-22-1601","article-title":"Phase II trial of pembrolizumab and anti-CD3 x anti-HER2 bispecific antibody-armed activated T cells in metastatic castration-resistant prostate cancer","volume":"29","author":"Vaishampayan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B114","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.eururo.2022.08.005","article-title":"Pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 cohort A study","volume":"83","author":"Yu","year":"2023","journal-title":"Eur Urol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-020-0254-y","article-title":"Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis","volume":"24","author":"Yuan","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B116","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2021.09.043","article-title":"Nivolumab plus docetaxel in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial","volume":"160","author":"Fizazi","year":"2022","journal-title":"Eur J Cancer"},{"key":"B117","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/jitc-2022-004761","article-title":"Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial","volume":"10","author":"Fizazi","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44514-2","article-title":"Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial","volume":"15","author":"Markowski","year":"2024","journal-title":"Nat Commun"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2703","article-title":"PD-L1 is highly expressed in Enzalutamide resistant prostate cancer","volume":"6","author":"Bishop","year":"2015","journal-title":"Oncotarget"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.08.011","article-title":"Avelumab combined with stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer: the phase 2 ICE-PAC clinical trial","volume":"81","author":"Kwan","year":"2022","journal-title":"Eur Urol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41467-021-20893-2","article-title":"CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy","volume":"12","author":"Rodriguez-Garcia","year":"2021","journal-title":"Nat Commun"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01501-x","article-title":"Counteracting CAR T cell dysfunction","volume":"40","author":"Poorebrahim","year":"2021","journal-title":"Oncogene"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: Elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.687822","article-title":"Obstacles and coping strategies of CAR-T cell immunotherapy in solid tumors","volume":"12","author":"Miao","year":"2021","journal-title":"Front Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.718686","article-title":"Gene-edited interleukin CAR-T cells therapy in the treatment of Malignancies: present and future","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.eururo.2019.08.014","article-title":"Challenges and prospects of chimeric antigen receptor T-cell therapy for metastatic prostate cancer","volume":"77","author":"Gorchakov","year":"2020","journal-title":"Eur Urol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-30","article-title":"Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice","volume":"14","author":"Hillerdal","year":"2014","journal-title":"BMC Cancer"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111339","article-title":"ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft","volume":"137","author":"Zhou","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf0108","article-title":"[amp]]gamma;\u03b4-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer","volume":"9","author":"Frieling","year":"2023","journal-title":"Sci Adv"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.06.014","article-title":"PSMA-directed CAR T cells combined with low-dose docetaxel treatment induce tumor regression in a prostate cancer xenograft model","volume":"18","author":"Alzubi","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"B132","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12967-019-02206-w","article-title":"IL-23 and PSMA-targeted duo-CAR T cells in Prostate Cancer Eradication in a preclinical model","volume":"18","author":"Wang","year":"2020","journal-title":"J Transl Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110807","article-title":"Dominant negative TGF\u03b2 receptor II and truncated TIM3 enhance the antitumor efficacy of CAR-T-cell therapy in prostate cancer","volume":"124","author":"Tang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T\u2009cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032712-095951","article-title":"Regulation of ligands for the NKG2D activating receptor","volume":"31","author":"Raulet","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1097\/ppo.0000000000000029","article-title":"NKG2D CARs as cell therapy for cancer","volume":"20","author":"Sentman","year":"2014","journal-title":"Cancer J"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0102","article-title":"Exploiting natural killer group 2D receptors for CAR T-cell therapy","volume":"13","author":"Demoulin","year":"2017","journal-title":"Future Oncol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12071969","article-title":"Co-expression of IL-7 improves NKG2D-based CAR T cell therapy on prostate cancer by enhancing the\u00a0expansion and inhibiting the apoptosis and exhaustion","volume":"12","author":"He","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B139","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","article-title":"Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells","volume":"35","author":"Du","year":"2019","journal-title":"Cancer Cell"},{"key":"B140","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/pcan.2016.49","article-title":"Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis","volume":"20","author":"Benzon","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-08-2262","article-title":"Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases","volume":"15","author":"Chavin","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-2584","article-title":"B7-H3: an attractive target for antibody-based immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B143","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41420-023-01453-7","article-title":"B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer","volume":"9","author":"Li","year":"2023","journal-title":"Cell Death Discovery"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-20-0446","article-title":"Targeting radiation-resistant prostate cancer stem cells by B7-H3 CAR T cells","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2012.10.123","article-title":"STEAP1 is overexpressed in cancers: a promising therapeutic target","volume":"429","author":"Moreaux","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.013690","article-title":"Cryo-electron microscopy structure and potential enzymatic function of human six-transmembrane epithelial antigen of the prostate 1 (STEAP1)","volume":"295","author":"Oosterheert","year":"2020","journal-title":"J Biol Chem"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1007\/s00418-020-01877-7","article-title":"Six-transmembrane epithelial antigen of the prostate 1 expression promotes ovarian cancer metastasis by aiding progression of epithelial-to-mesenchymal transition","volume":"154","author":"Jiao","year":"2020","journal-title":"Histochem Cell Biol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1042\/bsr20193169","article-title":"STEAP1 facilitates metastasis and epithelial-mesenchymal transition of lung adenocarcinoma via the JAK2\/STAT3 signaling pathway","volume":"40","author":"Huo","year":"2020","journal-title":"Biosci Rep"},{"key":"B149","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12032-018-1100-0","article-title":"Knockdown of STEAP1 inhibits cell growth and induces apoptosis in LNCaP prostate cancer cells counteracting the effect of androgens","volume":"35","author":"Gomes","year":"2018","journal-title":"Med Oncol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41467-023-37874-2","article-title":"Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy","volume":"14","author":"Bhatia","year":"2023","journal-title":"Nat Commun"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.25.14523","article-title":"STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors","volume":"96","author":"Hubert","year":"1999","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B152","doi-asserted-by":"publisher","first-page":"E4473","DOI":"10.1073\/pnas.1802354115","article-title":"Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer","volume":"115","author":"Lee","year":"2018","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.07.033","article-title":"Subgroups of castration-resistant prostate cancer bone metastases defined through an inverse relationship between androgen receptor activity and immune response","volume":"71","author":"Ylitalo","year":"2017","journal-title":"Eur Urol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220456","article-title":"Utilisation of the STEAP protein family in a diagnostic setting may provide a more comprehensive prognosis of prostate cancer","volume":"14","author":"Burnell","year":"2019","journal-title":"PloS One"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2018.06.022","article-title":"Membrane cholesterol modulates STEAP2 conformation during dynamic intracellular trafficking processes leading to broad subcellular distribution","volume":"370","author":"Hasegawa","year":"2018","journal-title":"Exp Cell Res"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1172\/jci169655","article-title":"Antitumor activity of AZD0754, a dnTGF\u03b2RII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer","volume":"133","author":"Zanvit","year":"2023","journal-title":"J Clin Invest"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0911397107","article-title":"Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker","volume":"107","author":"Zhang","year":"2010","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B158","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bbrc.2023.09.018","article-title":"F77 antigen is a promising target for adoptive T cell therapy of prostate cancer","volume":"680","author":"Grover","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"B160","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12935-024-03320-6","article-title":"Significance of PSCA as a novel prognostic marker and therapeutic target for cancer","volume":"24","author":"Nayerpour Dizaj","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1220586","article-title":"PSMA-targeted therapy for non-prostate cancers","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coi.2018.02.004","article-title":"NKG2D and its ligands in cancer","volume":"51","author":"Dhar","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701006","article-title":"B7-H3\/CD276: an emerging cancer immunotherapy","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1527312","article-title":"Advancing therapies in metastatic castration-resistant prostate cancer","volume":"19","author":"Baciarello","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"B165","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13020334","article-title":"Immunotherapy and immunotherapy combinations in metastatic castration-resistant prostate cancer","volume":"13","author":"Bansal","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03363-z","article-title":"A vaccine targeting mutant IDH1 in newly diagnosed glioma","volume":"592","author":"Platten","year":"2021","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1544882\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T04:06:17Z","timestamp":1741752377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1544882\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":166,"alternative-id":["10.3389\/fimmu.2025.1544882"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1544882","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"article-number":"1544882"}}